natgillin/translations-raw huggingface dataset:
The process of claim 28 wherein the malonic diester is diethyl malonate, the base is sodium t-butoxide, the solvent is N-methyl-2-pyrrolidinone and the mineral acid is sulfuric acid. 
Postupak u skladu s patentnim zahtjevom 28, gdje diester malonske kiseline je dietil-malonat, baza je natrijev t-butoksid, otapalo je N-metil-2-pirolidinon, a mineralna kiselina je sumporna kiselina.
The process of claim 29 wherein 2-methyl-3-nitropyridine is prepared. 
Postupak u skladu s patentnim zahtjevom 29, gdje se dobiva 2-metil-3-nitropiridin.
The process of claim 31 wherein the oxalate diester is diethyl oxalate, the solvent is tetrahydrofuran and the base is sodium ethoxide. 
Postupak u skladu s patentnim zahtjevom 31, gdje diester oksalne kiseline je dietil-oksalat, otapalo je tetrahidrofuran, a baza je natrijev etoksid.
The process of claim 32 wherein 2-hydroxy-3-(3-nitro-pyridin-2-yl)-acrylic acid ethyl ester is prepared. 
Postupak u skladu s patentnim zahtjevom 32, gdje se dobiva etilni ester 2-hidroksi-3-(3-nitropiridin-2-il) akrilne kiseline.
The process of claim 34 wherein the solvent is absolute ethanol and the catalyst is palladium on carbon. 
Postupak u skladu s patentnim zahtjevom 34, gdje otapalo je apsolutni etanol, a katalizator je paladij na ugljiku.
The process of claim 35 wherein 1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid ethyl ester is prepared. 
Postupak u skladu s patentnim zahtjevom 35, gdje se dobiva etilni ester 1H-pirolo[3,2-b]piridin-2-karboksilne kiseline.
The process of claim 37 wherein the solvent is methanol. 
Postupak u skladu s patentnim zahtjevom 37, gdje otapalo je metanol.
The process of claim 38 wherein 1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide is prepared. 
Postupak u skladu s patentnim zahtjevom 38, gdje se dobiva amid 1H-pirolo[3,2-b]piridin-2-karboksilne kiseline.
The process of claim 28 further comprising the step of adding an unsubstituted or a substituted 1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide, 1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid amide or 1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid amide, an excess amount of a suitable base, and a diaryldisulfide or a diheterocycledisulfide to a suitable solvent and heating to afford a compound of formula (I) wherein R1 is hydrogen. 
Postupak u skladu s patentnim zahtjevom 28, koji se dalje sastoji u koraku dodavanja nesupstituiranog ili supstituiranog amida 1H-pirolo[3,2-b]piridin-2-karboksilne kiseline, amida 1H-pirolo[3,2-c]piridin-2-karboksilne kiseline ili amida 1H-pirolo[2,3-c]piridin-2-karboksilne kiseline, suvišne količine pogodne baze, te diaril-disulfida ili diheterocikl-disulfida u pogodno otapalo, te grijanju kako bi se dobilo spoj formule (I), gdje R1 je vodik.
The process according to claim 41 wherein 3-phenylsulfanyl-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide is prepared. 
Postupak u skladu s patentnim zahtjevom 41, gdje se dobiva amid 3-fenilsulfanil-1H-pirolo[3,2-b]piridin-2-karboksilne kiseline.
The process according to claim 41 wherein 3-(3-fluorophenylsulfanyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid amide is prepared. 
Postupak u skladu s patentnim zahtjevom 41, gdje se dobiva amid 3-(3-fluorfenilsulfanil)-1H-pirolo[3,2-b] piridin-2-karboksilne kiseline.
A N-hydroxyamide derivative according to to any claims 1 to 3 wherein R2 is selected from optionally substituted C3-C8-cycloalkyl and optionally substituted heterocycloalkyl. 
Derivat N-hidroksiamida sukladno bilo kojem od zahtjeva 1 do 3, naznačen time, da R2 je izabran između ponekad supstituiranog C3-C8-cikloalkila i ponekad supstituiranog heterocikloalkila.
A N-hydroxyamide derivative according to any of the preceding claims wherein R5 and R6 are H and R4 and R7 can form together a -CH2- linkage. 
Derivat N-hidroksiamida sukladno bilo kojem od prethodnih zahtjeva, naznačen time, da R5 i R6 su H, a R4 i R7 mogu oblikovati poveznicu –CH2-.
A N-hydroxyamide derivative according to claim 1 having a Formula (Ib): wherein A is a carbon atom; 
Derivat N-hidroksiamida sukladno zahtjevu 1, a koji ima Formulu (Ib): [image] naznačen time, da A je ugljikov atom;
Use of a compound according to claims 1 to 20 as well as mixtures of these for the preparation of a medicament for the prophylaxis and/or treatment of inflammatory diseases, neurodegenerative diseases, cardiovascular diseases, stroke, cancer, pre-term labor, endometriosis, fibrosis and respiratory disorders. 
Uporaba spoja sukladno zahtjevima 1 do 20, kao i njihove mješavine, naznačena time, da se spojevi rabe u priređivanju lijeka za profilaksu i/ili tretmanu upalnih bolesti, neurodegenerativnih bolesti, kardiovaskularnih bolesti, kapi, raka, preuranjenih trudova, endometrioze, fibroze i respiratornih poremećaja.
Use according to claim 22 wherein said diseases are selected in the group including asthma, emphysema and chronic obstructive pulmonary disorders. 
Uporaba sukladno zahtjevu 22, naznačena time, da spomenute bolesti su izabrane iz skupine koja uključuje astmu, emfizem i kronične opstruktivne plućne poremećaje.
A compound according to Formula (IV): wherein A, R1, R2,R4, R5, R6, R7 and n are as defined in the preceding claims. 
Spoj skladno Formuli (IV): [image] naznačen time, da su A, R1, R2, R4, R5, R6, R7 te n definirani u prethodnim zahtjevima.
A compound according to claim 28 selected from the group: 
Spoj sukladno zahtjevu 28, naznačen time, da je izabran iz slijedeće skupine:
The transdermal delivery device of any one of claims 1 to 3, wherein the microspheres further comprise a polymer selected from the group consisting of polyesters, polyethers, poly(orthoesters), polysaccharides, cyclodextrins, chitosans, poly (E-caprolactones), polyanhydrides, albumin, blends and copolymers thereof and mixtures thereof. 
Sredstvo za transdermalno davanje prema zahtjevu 1, naznačeno time da mikrosfere nadalje sadrže polimer odabran iz skupine koja se sastoji od poliestera, polietera, poli (ortoestera), polisaharida, ciklodekstrina, citosana, poli (Σ-kaprolaktona), polianhidrida, albumina, njihovih mješavina i kopolimera i njihovih smjesa.
A compound as claimed in claim 1, selected from among the following group: 
Spoj prema patentnom zahtjevu 1, naznačen time što je izabran iz slijedeće grupe:
A process for preparing a compound of the general formula 1 as claimed in claim1, which comprises: 
Postupak za pripremu spoja opće formule 1 prema patentnom zahtjevu 1, naznačen time što sadrži:
while either of R5 or R10 group is a halogen atom such as bromo, chloro or iodo, and the other is hydrogen; 
dok je bilo koja od R5 ili R10 grupe jednaka atom halogena kao što je bromo, kloro ili jodo, i druga je vodik;
using a Pd(0) or Pd (II) derivative as a catalyst, 
primjenom Pd(0) ili Pd (II) derivata kao katalizatora.
Use of compound of formula (I), according to claim 8, preferably in CNS disorders, such as psychosis, paraphrenia, anxiety, depression, mania, schizophrenia, schizophreniform disorders, migraine headache, drug addiction, convulsive disorders, personality disorders, hypertension, autism, post-traumatic stress syndrome, alcoholism, panic attacks, obsessive-compulsive disorders, chronobiological abnormalities and circadian rhythms, cognitive memory disorders e.g. 
Primjena spoja formule (I), prema patentnom zahtjevu 8, naznačena time što se poželjno koristi kod poremećaja CNS-a, kao što su psihoza, parafrenija, anksioznost, depresija, manija, šizofrenija, šizofreniformni poremećaji, migrenozne glavobolje, ovisnost o lijekovima, konvulzivni poremećaji, poremećaji ličnosti, hipertenzija, autizam, post-traumatski stresni sindrom, alkoholizam, napadi panike, opsesivno-kompulzivni poremećaji, kronobiološki abnormaliteti i cirkadijalni ritam, kognitivni poremećaji pamćenja npr.
Alzheimer's disease and age-related cognitive decline, ADHD (Attention Deficient Disorder/ Hyperactivity Syndrome), amylotrophic lateral sclerosis, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, panic attacks, and also disorders associated with spinal trauma and / or head injury such as hydrocephalus and also mild cognitive impairment and other neurodegenerative disorders like Alzheimer's disease, Parkinsonism and Huntington's chorea. 
Alzheimer-ova bolest i opadanje kognitivnih funkcija starenjem, ADHD (poremećaj oštećenja pažnje/sindrom hiperaktivnosti), amilotrofna lateralna skleroza, apstinencija kod zloupotrebe narkotika kao što je kokain, etanol, nikotin i benzodiazepini, napadi panike, i također poremećaji povezani sa povredom kičme i/ili povredom glave kao što su hidrocefalus i također blago pogoršanje kognitivnih funkcija i drugi neurodegenerativni poremećaji kao što su Alzheimer-ova bolest, Parkinsonizam i Huntington-ova korea.
Use of compound of formula (I), according to claim 8, preferably in GI (Gastrointestinal) disorders, such as IBS (Irritable bowel syndrome) or chemotherapy induced emesis. 
Primjena spoja formule (I) prema patentnom zahtjevu 8, naznačena time što se poželjno koristi kod GI (gastrointestinalnih) poremećaja, kao što je IBS (sindrom iritabilnog crijeva) ili povraćanja induciranog kemoterapijom.
Use of compound of formula (I), according to claim 8, preferably in modulation of eating disorders. 
Primjena spoja formule (I), prema patentnom zahtjevu 8, naznačena time što se poželjno koristi u modulaciji poremećaja ishrane.
2, namely the compound of formula 
2, odnosno spoj formule [image]
A process for preparing a compound according to claim 1 characterised by reacting an intermediate of formula (II) wherein M represents hydrogen or an alkali metal, with a compound of formula (III), in the presence of a base: 
Postupak priprave spoja prema zahtjevu 1, naznačen time da se provodi reakcija međuspojeva formule (II) pri čemu M predstavlja vodik ili alkalni metal, sa spojem formule (III), uz prisutstvo baze:
A solution containing: 
Otopina koja sadrži:
a solvent selected from the group consisting of CH2Cl2, CHCl3, CCl4, perfluorohexane, perfluoroheptane; 
otapalo odabrano iz skupine sastavljene od CH2Cl2, CHCl3, CCl4, perfluorheksana, perfluorheptana;
characterized in that the compound of formula (I) is present in a concentration not higher than 20% by weight. 
naznačena time da je spoj formule (I) prisutan u koncentraciji ne većoj od 20% masenih.
A process according to claim 6 for preparing a compound of formula (I) wherein X is Br. 
Postupak prema zahtjevu 6 za pripremu spoja formule (I), naznačen time da X je Br.
or G11 is C, which taken together with the carbon to which it is attached forms a C=C double bond which is substituted with R5 and G111. 
ili G11 je C, uzet zajedno s ugljikom za koji je vezan formira C=C dvostruku vezu koja je supstituirana s R5 i G111.
The compound of claim 35 wherein the ocular condition is ocular or macular edema, ocular neovascular disease, seleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser treatment complications, conjunctivitis, Stargardt's disease, Eales disease, retinopathy, or macular degeneration. 
Spoj prema patentnom zahtjevu 35, naznačen time što je bolest oka - očni edem ili makularni edem, očna neovaskularna bolest, seleritis, radijalna keratotomija, uveitis, vitritis, miopija, kongenitalne anomalije optičkog živca, kronična ablacija retine, komplikacije poslije laserskog tretmana, konjuktivitis, Stargardtova bolest, Eales bolest, retinopatija ili makularna degeneracija.
The compound of claim 37 wherein the condition mediated by protein kinase activity is atherosclerosis, restenosis, ischemia/reperfusion injury, vascular occlusion, venous malformation, or carotid obstructive disease. 
Spoj prema patentnom zahtjevu 37, naznačen time što je stanje koje je posredovano preko aktivnosti protein kinaze ateroskleroza, restenoza, ishemija/reperfuzijska povreda, vaskularna okluzija, venska malformacija ili karotidna opstruktivna bolest.
The compound of claim 39 wherein the cancer is a solid tumor, a sarcoma, fibrosarcoma, osteoma, melanoma, retinoblastoma, a rhabdomyosarcoma, glioblastoma, neuroblastoma, teratocarcinoma, an hematopoietic malignancy, malignant ascites, Kaposi's sarcoma, Hodgkin's disease, lymphoma, myeloma, or leukemia. 
Spoj prema patentnom zahtjevu 39, naznačen time što je rak solidni tumor, sarkom, fibrosarkom, osteom, melanom, retinoblastom, rabdomiosarkom, glioblastom, neuroblastom, teratokarcinom, hematopoetski malignitet, maligni ascites, Kaposijev sarkom, Hodgkinova bolest, limfom, mijelom ili leukemija.
The compound of claim 35 wherein the diabetic condition is insulin-dependent diabetes mellitus glaucoma, diabetic retinopathy, or microangiopathy. 
Spoj prema patentnom zahtjevu 35, naznačen time što je dijabetičko stanje - inzulin-zavisni dijabetes melitus glaukom, dijabetička retinopatija ili mikroangiopatija.
The compound of claim 29 wherein the protein kinase activity is involved in T cell activation, B cell activation, mast cell degranulation, monocyte activation, signal transduction, apoptosis, the potentiation of an inflammatory response or a combination thereof. 
Spoj prema patentnom zahtjevu 29, naznačen time što je aktivnost protein kinaze uključena u T staničnu aktivaciju, B staničnu aktivaciju, degranulaciju mastocita, aktivaciju monocita, prijenos signala, apoptozu, pojačavanje inflamatornog odgovora ili njihovu kombinaciju.
is a (2-4C)alkyl and is substituted by two or more fluorine groups; and 
je (2-)alkil i je supstituiran sa dvije ili više skupina fluora; i
A compound of the Formula (I) as claimed in claim 1 wherein R1 is ethyl, propyl or butyl and is substituted by two or more fluorine groups. 
Spoj sa formulom (I), prema zahtjevu 1, naznačen time, da R1 je etil, propil ili butil i je supstituiran sa dvije ili više skupina fluora.
A compound of the Formula (I) as claimed in claim 1 or claim 2 wherein R1 is ethyl, propyl or butyl and is substituted by two to six fluorine groups. 
Spoj sa formulom (I), prema zahtjevu 1 ili 2, naznačen time, da R1 je etil, propil ili butil i da je supstituiran sa dvije ili šest skupina fluora.
A compound of the Formula (I) as claimed in claims 1 to 4 selected from 
Spoj sa formulom (I), prema zahtjevima od 1 do 4, naznačen time, da je izabran iz
A process for the preparation of a compound of the Formula (I) as claimed in any one of claims 1 to 5, or a pharmaceutically-acceptable salt thereof, which comprises the reaction of a phenoxy piperidine of the Formula (II) with a sulfonyl chloride of the Formula (III) wherein R1 and R2 are as defined in claim 1 and wherein any functional group is protected if necessary, and 
Postupak za pripravu spoja formule (I), prema bilo kojem od zahtjeva od 1 do 5 ili njegova farmaceutski prihvatljiva sol, naznačen time, da uključuje reakciju fenoksi piperidina sa formulom (II) sa sulfonil kloridom sa formulom (III), [image] pri čemu su R1 i R2 definirani u zahtjevu 1 i gdje je bilo koja funkcionalna skupina zaštićena ukoliko je to potrebno, i
removing any protecting groups; and 
odstranjivanje bilo koje zaštitne skupine; i
two R5 aliphatic groups may be optionally taken together with the carbon to which they are bound to form a C3-4 cycloalkyl ring; 
dvije R5 alifatske skupine mogu biti opcionalno uzete zajedno s ugljikom na koji su vezane kako bi činile C3-4 cikloalkilni prsten;
is a C1-3 aliphatic group; and Ring C is a 6-membered heteroaryl ring having 1-2 nitrogens, wherein: 
je C1-3 alifatska skupina; i prsten C je 6-člani heteroarilni prsten koji ima 1-2 dušika, gdje:
Ring C is substituted with 1-3 groups selected from R6; 
je prsten C supstituiran s 1-3 skupine odabrane od R6;
for example wherein R3 is a C1-3 alkyl group optionally substituted with an OH group; 
na primjer gdje R3 je C1-3 alkilna skupina opcionalno supstituirana s OH skupinom;
such as wherein R3 is a C1-3 alkyl group substituted with an OH group; 
primjerice gdje R3 je C1-3 alkilna skupina supstituirana s OH skupinom;
for example wherein R3 is a C1-3 alkyl group substituted with methyl, gem-dimethyl, ethyl, propyl, isopropyl, cyclopropyl, or cyclobutyl, and an OH group. 
na primjer gdje R3 je C1-3 alkilna skupina supstituirana s metil, gem-dimetil, etil, propil, izopropil, ciklopropil, ili ciklobutil, i OH skupinom.
V is nitrogen and R3 is substituted with two groups independently selected from R5 and OH; or 
V je dušik i R3 je supstituiran s dvije skupine neovisno odabrane od R5 i OH; ili
V is CH and R3 is substituted with two groups independently selected from R5 and OH; 
V je CH i R3 je supstituiran s dvije skupine neovisno odabrane od R5 i OH;
for example wherein R3 is substituted with one R5 group and one OH group. 
na primjer gdje R3 je supstituiran s jednom R5 skupinom i jednom OH skupinom.
Ring C is substituted with 1-3 groups selected from R6; 
prsten C je supstituiran s 1-3 skupine odabrane od R6;
is substituted with 0-3 groups independently selected from OH, R5, or OR5; 
je supstituiran s 0-3 skupine neovisno odabrane od OH, R5, ili OR5;
is a C1-3 aliphatic group; or wherein said compound is of formula VIIH, or VIIJ: or a pharmaceutically acceptable salt thereof, wherein: 
je C1-3 alifatska skupina; ili gdje navedeni spoj je formule VIIH, ili VIIJ: [image] ili njihova farmaceutski prihvatljiva sol, gdje:
A compound selected from the group consisting of: 
Spoj odabran od skupine koja se sastoji od:
A composition comprising a compound according to any one of claims 1-10, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 
Sastav koji sadrži spoj prema bilo kojem zahtjevu od 1 do 10, i farmaceutski prihvatljiv nosač, adjuvans, ili sredstvo.
A compound according to any one of claims 1 to 10, or a composition according to claim 11, for use according to claim 17, wherein the bacterial infection to be treated is selected from one or more of the following: a urinary tract infection, a respiratory infection, pneumonia, prostatitis, a skin or soft tissue infection, an intraabdominal infection, a blood stream infection, or an infection of febrile neutropenic patients. 
Spoj prema bilo kojem zahtjevu od 1 do 10, ili sastav prema zahtjevu 11, za upotrebu prema zahtjevu 17, naznačeni time da je bakterijska infekcija koju treba liječiti odabrana od jedne ili više od sljedećih: infekcija urinarnog trakta, respiratorna infekcija, upala pluća, prostatitis, infekcija kože ili mekog tkiva, intraabdominalna infekcija, infekcija krvotoka, ili infekcija pacijenata oboljelih od febrilne neutropenije.
Use of a compound according to any one of claims 1 to 10, or of a composition according to claim 11, in the manufacture of a medicament for treating a bacterial infection characterized by the presence of one or more of the following: Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Enterobacter sps., Proteus sps., Pseudomonas aeruginosa, E. coli, Serratia marcesens, Staphylococcus aureus, Staphylococcus saprophyticus, Coag. 
Upotreba spoja prema bilo kojem zahtjevu od 1 do 10, ili sastava prema zahtjevu 11, naznačeni time da su za proizvodnju lijeka za liječenje bakterijske infekcije karakterizirane prisutnošću jedne ili više od sljedećih: Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Enterococcus faecium, Klebsiella pneumoniae, Enterobacter sps., Proteus sps., Pseudomonas aeruginosa, E. coli, Serratia marcesens, Staphylococcus aureus, Staphylococcus saprophyticus, Coag.
Staph, Haemophilus influenzae, Bacillus anthracis, Mycoplasma pneumoniae, Moraxella catarralis, Chlamydia pneumoniae, Legionella pneumophila, Staphylococcus epidermidis, Mycobacterium tuberculosis, or Heliobacter pylori; or selected from one or more of the following: a urinary tract infection, a respiratory infection, pneumonia, prostatitis, a skin or soft tissue infection, an intraabdominal infection, a blood stream infection, or an infection of febrile neutropenic patients. 
Staph, Haemophilus influenzae, Bacillus anthracis, Mycoplasma pneumoniae, Moraxella catarralis, Chlamydia pneumoniae, Legionella pneumophila, Staphylococcus epidermidis, Mycobacterium tuberculosis, ili Heliobacter pylori; ili odabrane od jedne ili više od sljedećih: infekcija urinarnog trakta, respiratorna infekcija, upala pluća, prostatitis, infekcija kože ili mekog tkiva, intraabdominalna infekcija, infekcija krvotoka, ili infekcija pacijenata oboljelih od febrinle neutropenije.
obtaining the (4S, 6S) enantiomer by selectively precipitating and recovering the camphorsulfonic acid salt thereof (dorzolamide camphorsulfonate) of formula (III) and 
dobivanjem (4S, 6S) enantiomera selektivno precipitirajući i izolirajući sol kamforsulfonske kiseline (dorzolamid kamforsulfonat) formule (III) [image] i
A process according to claim 1, wherein after said isolation by precipitation, dorzolamide camphorsulfonate is submitted to a further purification through recrystallization to promote the enantiomeric enrichment of the enantiomer achieved and to improve its overall purity profile. 
Postupak prema zahtjevu 1, gdje se nakon navedene izolacije precipitacijom, dorzolamid podvrgne daljnjem pročišćavanju putem prekristalizacije kako bi se poboljšalo enantiomersko obogaćenje dobivenog enantiomera i kako bi se poboljšao njegov ukupni stupanj čistoće.
The method of Claim 1, wherein the external gas pressure is at least about 200 psi. 
Postupak u skladu s patentnim zahtjevom 1, gdje pritisak vanjskog plina iznosi najmanje 1,38 MPa (200 psi).
The method of Claim 1 or 2, wherein said external gas pressure is at least about 500 psi. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, gdje navedeni pritisak vanjskog plina iznosi najmanje 3,45 MPa (500 psi).
The method of Claim 13, wherein said surfactant is an emulsifier. 
Postupak u skladu s patentnim zahtjevom 13, gdje navedeni surfaktant je emulgator.
The method of Claim 16, wherein said buffering agent is a salt of an organic or inorganic acid. 
Postupak u skladu s patentnim zahtjevom 16, gdje navedeno pufersko sredstvo je sol organske ili anorganske kiseline.
The method of Claim 17, wherein said salt is selected from the group consisting of a sodium salt, potassium salt, magnesium salt, or calcium salt, of citric acid, fumaric acid, malic acid, phosphoric acid, or mixture thereof. 
Postupak u skladu s patentnim zahtjevom 17, gdje navedenu sol se bira iz skupine koju čine natrijeva sol, kalijeva sol, magnezijeva sol ili kalcijeva sol limunske kiseline, fumarne kiseline, jabučne kiseline, fosforne kiseline, ili njihova smjesa.
The method of any one of Claims 1 to 20, wherein said particles have an internal void volume of at least about 50% before subjecting to said external gas pressure. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 20, gdje volumen unutarnje šupljine navedenih čestica iznosi najmanje 50 % prije podvrgavanja tlaku vanjskog plina.
The method of Claim 31, wherein gas used in said gas-injected spray-drying is selected from the group consisting of air, nitrogen, carbon dioxide, nitrous oxide, and mixture thereof. 
Postupak u skladu s patentnim zahtjevom 31, gdje plin kojeg se upotrebljava u sušenju raspršivanjem injektiranjem plinom se bira iz skupine koju čine zrak, dušik, ugljični dioksid, te njihova smjesa.
The method of Claim 1, wherein the external gas pressure is at least 1.38MPa (200 psi) 
Postupak u skladu s patentnim zahtjevom 1, gdje pritisak vanjskog plina iznosi najmanje 1,38 MPa (200 psi).
The method of Claim 1 or 2, wherein said external gas pressure is at least 3.45MPa (500 psi) 
Postupak u skladu s patentnim zahtjevom 1 ili 2, gdje navedeni pritisak vanjskog plina iznosi najmanje 3,45 MPa (500 psi).
The method of any one of Claims 1 to 20, wherein said particles have an internal void volume of at least 50% before subjecting to said external gas pressure. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 20, gdje volumen unutarnje šupljine navedenih čestica iznosi najmanje 50 % prije podvrgavanja tlaku vanjskog plina.
The composition of claim 1, comprising a conjugate from both of serogroups A and C. 
Sastav prema zahtjevu 1, naznačen time da sadrži konjugate od obje serogrupe A i C.
The composition of claim 1 or claim 2, comprising a conjugate from all of serogroups A, C, W135 and Y. 
Sastav prema zahtjevu 1 ili 2, naznačen time da sadrži konjugate od svih serogrupa A, C, W135 i Y.